<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492944</url>
  </required_header>
  <id_info>
    <org_study_id>CIN_Lumason Crohns_001</org_study_id>
    <nct_id>NCT03492944</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason</brief_title>
  <official_title>Contrast-Enhanced Ultrasound Evaluation of Bowel Wall Inflammation in Pediatric Crohn's Disease: Comparison to CT and MRI Enterography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to compare contrast-enhanced ultrasound to CT and MRI for the
      detection and quantification of intestinal inflammation in the the setting of pediatric small
      bowel Crohns disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will investigate the use of an FDA-approved ultrasound microbubble
      contrast agent (Lumason; Bracco Diagnostics) in pediatric and adult Crohn's disease patients
      undergoing either MR enterography (MRE, or MRI of the bowel) or CT enterography (CTE, or CT
      of the bowel). In April 2016, Lumason was FDA approved for intravenous administration and
      imaging of the liver in children. Imaging of the bowel will employ an identical
      administration method to that described for liver imaging, but the ultrasound transducer will
      be placed over the affected intestines as opposed to liver.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of bowel wall enhancement</measure>
    <time_frame>2 years</time_frame>
    <description>Percent hyperenhancement (compared to normal bowel loops)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Disease Status for imaged section</measure>
    <time_frame>2 years</time_frame>
    <description>status of inactive, mild activity, moderate activity and severe activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of mesenteric inflammation</measure>
    <time_frame>2 years</time_frame>
    <description>Inflammation assessed as none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Bowel Wall Thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Measured</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Ultrasound Microbubble Contrast Agent</arm_group_label>
    <description>All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultrasound Microbubble Contrast Agent</intervention_name>
    <description>Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel</description>
    <arm_group_label>Ultrasound Microbubble Contrast Agent</arm_group_label>
    <other_name>Lumason</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound Imaging</intervention_name>
    <description>Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel</description>
    <arm_group_label>Ultrasound Microbubble Contrast Agent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to recruit approximately 25 subjects, 10-18 years of age, with known small bowel
        Crohn disease undergoing clinically indicated Computed Tomography Enterography (CTE) or
        Magnetic Resonance Enterography (MRE)imaging
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologic evidence of small bowel Crohn's disease, or clinical evidence of disease
             (including radiologic confirmation [either CT or MRI] and receiving medical therapy
             for Crohn's disease).

          -  Between ages 10 and 18 years.

          -  Undergoing clinically-indicated CTE or MRE with evidence of active disease based on
             pediatric gastroenterologist clinical assessment

        Exclusion Criteria:

          -  Patients under the age of 10 or over the age of 18.

          -  Pregnancy or breast feeding. Urine pregnancy testing will be performed on all female
             study participants of reproductive potential.

          -  Obesity/body habitus preventing visualization of small bowel affected by Crohn's
             disease by ultrasound (Body mass index ≥30 kg/m2

          -  Subject inability/unwillingness to consent or child assent, including severe
             developmental delay/mental retardation.

          -  Prior allergic-like reaction or other severe adverse event to Lumason or any of the
             active ingredients in Lumason (SPECIFIC CONTRAINDICATION from Package Insert).

          -  Known unstable cardiopulmonary conditions (including any history of acute myocardial
             infarction/acute coronary artery syndrome, arrhythmia, and congestive heart failure),
             ongoing acute or chronic kidney disease (eGFR &lt;30 ml/min), moderate/severe chronic
             lung disease, and end-stage liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Dillman, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Imbus, BA</last_name>
    <phone>513-636-9403</phone>
    <email>rebecca.imbus@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan Dillman, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adler J, Punglia DR, Dillman JR, Polydorides AD, Dave M, Al-Hawary MM, Platt JF, McKenna BJ, Zimmermann EM. Computed tomography enterography findings correlate with tissue inflammation, not fibrosis in resected small bowel Crohn's disease. Inflamm Bowel Dis. 2012 May;18(5):849-56. doi: 10.1002/ibd.21801. Epub 2011 Jun 24.</citation>
    <PMID>21710535</PMID>
  </reference>
  <reference>
    <citation>Girlich C, Jung EM, Huber E, Ott C, Iesalnieks I, Schreyer A, Schacherer D. Comparison between preoperative quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and operative macroscopic findings and results of histopathological scoring in Crohn's disease. Ultraschall Med. 2011 Apr;32(2):154-9. doi: 10.1055/s-0029-1245398. Epub 2010 May 6. Erratum in: Ultraschall Med. 2011 Dec;32 Suppl 2:E1.</citation>
    <PMID>20449794</PMID>
  </reference>
  <reference>
    <citation>Quaia E, Migaleddu V, Baratella E, Pizzolato R, Rossi A, Grotto M, Cova MA. The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn's disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment. Eur J Radiol. 2009 Mar;69(3):438-44. doi: 10.1016/j.ejrad.2008.10.029. Epub 2008 Dec 12.</citation>
    <PMID>19070446</PMID>
  </reference>
  <reference>
    <citation>Wong DD, Forbes GM, Zelesco M, Mason R, Pawlik J, Mendelson RM. Crohn's disease activity: quantitative contrast-enhanced ultrasound assessment. Abdom Imaging. 2012 Jun;37(3):369-76. doi: 10.1007/s00261-011-9792-z.</citation>
    <PMID>21830051</PMID>
  </reference>
  <reference>
    <citation>De Franco A, Di Veronica A, Armuzzi A, Roberto I, Marzo M, De Pascalis B, De Vitis I, Papa A, Bock E, Danza FM, Bonomo L, Guidi L. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. Radiology. 2012 Feb;262(2):680-8. doi: 10.1148/radiol.11110440. Epub 2011 Dec 12.</citation>
    <PMID>22157203</PMID>
  </reference>
  <reference>
    <citation>Girlich C, Schacherer D, Jung EM, Schreyer A, Büttner R. Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn's disease. Eur J Radiol. 2012 Jun;81(6):1105-9. doi: 10.1016/j.ejrad.2011.02.054. Epub 2011 Mar 24.</citation>
    <PMID>21439749</PMID>
  </reference>
  <reference>
    <citation>Ripollés T, Martínez MJ, Paredes JM, Blanc E, Flors L, Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology. 2009 Oct;253(1):241-8. doi: 10.1148/radiol.2531082269. Epub 2009 Jul 27.</citation>
    <PMID>19635834</PMID>
  </reference>
  <reference>
    <citation>Malagò R, D'Onofrio M, Mantovani W, D'Alpaos G, Foti G, Pezzato A, Caliari G, Cusumano D, Benini L, Pozzi Mucelli R. Contrast-enhanced ultrasonography (CEUS) vs. MRI of the small bowel in the evaluation of Crohn's disease activity. Radiol Med. 2012 Mar;117(2):268-81. doi: 10.1007/s11547-011-0783-5. Epub 2012 Jan 21.</citation>
    <PMID>22271005</PMID>
  </reference>
  <reference>
    <citation>Quaia E, De Paoli L, Stocca T, Cabibbo B, Casagrande F, Cova MA. The value of small bowel wall contrast enhancement after sulfur hexafluoride-filled microbubble injection to differentiate inflammatory from fibrotic strictures in patients with Crohn's disease. Ultrasound Med Biol. 2012 Aug;38(8):1324-32. doi: 10.1016/j.ultrasmedbio.2012.04.008. Epub 2012 Jun 13.</citation>
    <PMID>22698508</PMID>
  </reference>
  <reference>
    <citation>Schirin-Sokhan R, Winograd R, Tischendorf S, Wasmuth HE, Streetz K, Tacke F, Trautwein C, Tischendorf JJ. Assessment of inflammatory and fibrotic stenoses in patients with Crohn's disease using contrast-enhanced ultrasound and computerized algorithm: a pilot study. Digestion. 2011;83(4):263-8. doi: 10.1159/000321389. Epub 2011 Jan 28.</citation>
    <PMID>21273775</PMID>
  </reference>
  <reference>
    <citation>Riccabona M, Avni FE, Damasio MB, Ording-Müller LS, Blickman JG, Darge K, Lobo ML, Papadopoulou F, Vivier PH, Willi U. ESPR Uroradiology Task Force and ESUR Paediatric Working Group--Imaging recommendations in paediatric uroradiology, part V: childhood cystic kidney disease, childhood renal transplantation and contrast-enhanced ultrasonography in children. Pediatr Radiol. 2012 Oct;42(10):1275-83. doi: 10.1007/s00247-012-2436-9. Epub 2012 Sep 22.</citation>
    <PMID>23001574</PMID>
  </reference>
  <reference>
    <citation>Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol. 2008 Dec 15;102(12):1742-6. doi: 10.1016/j.amjcard.2008.08.019. Epub 2008 Oct 23.</citation>
    <PMID>19064035</PMID>
  </reference>
  <reference>
    <citation>McCarville MB, Kaste SC, Hoffer FA, Khan RB, Walton RC, Alpert BS, Furman WL, Li C, Xiong X. Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data. Pediatr Radiol. 2012 Jul;42(7):824-33. doi: 10.1007/s00247-011-2338-2. Epub 2012 Jan 17.</citation>
    <PMID>22249601</PMID>
  </reference>
  <reference>
    <citation>Dillman JR, Strouse PJ, Ellis JH, Cohan RH, Jan SC. Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast material in children. AJR Am J Roentgenol. 2007 Jun;188(6):1643-7. Erratum in: AJR Am J Roentgenol. 2007 Sep;189(3):512.</citation>
    <PMID>17515388</PMID>
  </reference>
  <reference>
    <citation>Wang CL, Cohan RH, Ellis JH, Adusumilli S, Dunnick NR. Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69,657 intravenous injections. Radiology. 2007 Apr;243(1):80-7. Erratum in: Radiology. 2015 Jan;274(1):307.</citation>
    <PMID>17392249</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research data including identifying information about participants will only be accessible to CCHMC study personnel. De-identified data including images will be shared with scientists at Bracco Diagnostics. No identifiable data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

